Do analysts recommend TMDIF or CLGN?

CollPlant Biotechnologies has a consensus price target of $11.50, suggesting a potential upside of 3,406.10%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer CLGN or ZJYL?

CollPlant Biotechnologies presently has a consensus target price of $11.50, suggesting a potential upside of 3,406.10%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CLGN or ZJYL?

Jin Medical International has higher revenue and earnings than CollPlant Biotechnologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CollPlant Biotechnologies $2.37M 2.00 -$11.49M -$1.45 N/A Jin Medical International $20.69M 0.86 $1.19M N/A N/A

CollPlant Biotechnologies (CLGN) Competitors

$0.33 +0.02 (+5.03%)

Closing price 02:50 PM Eastern

Extended Trading

$0.33 0.00 (-0.61%)

As of 04:10 PM Eastern

Compare

CLGN vs. ICU, IRIX, TMDIF, HIND, and ZJYL

Should you buy CollPlant Biotechnologies stock or one of its competitors? MarketBeat compares CollPlant Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CollPlant Biotechnologies include SeaStar Medical (ICU), IRIDEX (IRIX), Titan Medical (TMDIF), Vyome (HIND), and Jin Medical International (ZJYL). These companies are all part of the "medical equipment" industry.

How does CollPlant Biotechnologies compare to SeaStar Medical?

CollPlant Biotechnologies (NASDAQ:CLGN) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

In the previous week, CollPlant Biotechnologies' average media sentiment score of 0.00 equaled SeaStar Medical'saverage media sentiment score.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
SeaStar Medical	Neutral

CollPlant Biotechnologies presently has a consensus target price of $11.50, indicating a potential upside of 3,406.10%. SeaStar Medical has a consensus target price of $8.00, indicating a potential upside of 108.28%. Given CollPlant Biotechnologies' higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than SeaStar Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CollPlant Biotechnologies has higher revenue and earnings than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.00	-$11.49M	-$1.45	N/A
SeaStar Medical	$1.23M	12.49	-$12.15M	-$4.80	N/A

CollPlant Biotechnologies has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.05, meaning that its stock price is 205% less volatile than the broader market.

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 0.7% of SeaStar Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CollPlant Biotechnologies has a net margin of -683.68% compared to SeaStar Medical's net margin of -828.62%. SeaStar Medical's return on equity of -146.29% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
SeaStar Medical	-828.62%	-146.29%	-96.48%

Summary

CollPlant Biotechnologies beats SeaStar Medical on 9 of the 12 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to IRIDEX?

CollPlant Biotechnologies (NASDAQ:CLGN) and IRIDEX (NASDAQ:IRIX) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

CollPlant Biotechnologies presently has a consensus target price of $11.50, indicating a potential upside of 3,406.10%. IRIDEX has a consensus target price of $3.00, indicating a potential upside of 226.44%. Given CollPlant Biotechnologies' higher probable upside, equities analysts clearly believe CollPlant Biotechnologies is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CollPlant Biotechnologies has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, IRIDEX has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

IRIDEX has higher revenue and earnings than CollPlant Biotechnologies. IRIDEX is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.00	-$11.49M	-$1.45	N/A
IRIDEX	$52.67M	0.30	-$4.44M	-$0.19	N/A

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 20.1% of IRIDEX shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 8.6% of IRIDEX shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, IRIDEX had 2 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 2 mentions for IRIDEX and 0 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 equaled IRIDEX'saverage media sentiment score.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
IRIDEX	Neutral

IRIDEX has a net margin of -6.23% compared to CollPlant Biotechnologies' net margin of -683.68%. IRIDEX's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
IRIDEX	-6.23%	N/A	-11.16%

Summary

IRIDEX beats CollPlant Biotechnologies on 7 of the 13 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Titan Medical has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	1.04	$6.95M	$0.05	3.21
CollPlant Biotechnologies	$2.37M	2.00	-$11.49M	-$1.45	N/A

CollPlant Biotechnologies has a consensus price target of $11.50, suggesting a potential upside of 3,406.10%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Titan Medical's average media sentiment score of 0.00 equaled CollPlant Biotechnologies'average media sentiment score.

Company	Overall Sentiment
Titan Medical	Neutral
CollPlant Biotechnologies	Neutral

Titan Medical has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Titan Medical's return on equity of -82.31% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Summary

Titan Medical and CollPlant Biotechnologies tied by winning 7 of the 14 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Vyome?

CollPlant Biotechnologies (NASDAQ:CLGN) and Vyome (NASDAQ:HIND) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Vyome has lower revenue, but higher earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.00	-$11.49M	-$1.45	N/A
Vyome	$320K	47.60	-$10.26M	-$12.27	N/A

In the previous week, Vyome had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 1 mentions for Vyome and 0 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 equaled Vyome'saverage media sentiment score.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
Vyome	Neutral

Vyome has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Vyome's return on equity of -203.92% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Vyome	N/A	-203.92%	-134.16%

CollPlant Biotechnologies presently has a consensus target price of $11.50, suggesting a potential upside of 3,406.10%. Vyome has a consensus target price of $15.00, suggesting a potential upside of 591.24%. Given CollPlant Biotechnologies' higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 22.1% of Vyome shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 33.0% of Vyome shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CollPlant Biotechnologies has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Vyome has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Summary

Vyome beats CollPlant Biotechnologies on 11 of the 15 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Jin Medical International?

CollPlant Biotechnologies (NASDAQ:CLGN) and Jin Medical International (NASDAQ:ZJYL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

21.7% of CollPlant Biotechnologies shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jin Medical International has higher revenue and earnings than CollPlant Biotechnologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.00	-$11.49M	-$1.45	N/A
Jin Medical International	$20.69M	0.86	$1.19M	N/A	N/A

In the previous week, Jin Medical International had 2 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 2 mentions for Jin Medical International and 0 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 equaled Jin Medical International'saverage media sentiment score.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
Jin Medical International	Neutral

CollPlant Biotechnologies has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.34, indicating that its share price is 634% more volatile than the broader market.

Jin Medical International has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Jin Medical International's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Jin Medical International	N/A	N/A	N/A

CollPlant Biotechnologies presently has a consensus target price of $11.50, suggesting a potential upside of 3,406.10%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Jin Medical International beats CollPlant Biotechnologies on 7 of the 13 factors compared between the two stocks.

Get CollPlant Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLGN vs. The Competition

Export

Metric	CollPlant Biotechnologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.74M	$3.66B	$6.82B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.23	20.80	27.00	24.20
Price / Sales	2.00	322.97	519.38	94.43
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.68	8.17	10.67	6.26
Net Income	-$11.49M	$23.81M	$3.60B	$331.76M
7 Day Performance	-10.14%	-1.12%	-0.32%	-1.10%
1 Month Performance	-2.70%	2.64%	1.88%	-1.26%
1 Year Performance	-85.36%	45.50%	25.50%	18.84%

CollPlant Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLGN CollPlant Biotechnologies	2.0139 of 5 stars	$0.33 +5.0%	$11.50 +3,406.1%	-84.6%	$4.74M	$2.37M	N/A	70
ICU SeaStar Medical	2.3081 of 5 stars	$4.80 +0.2%	$8.00 +66.7%	-45.8%	$19.15M	$1.23M	N/A	2
IRIX IRIDEX	1.3609 of 5 stars	$1.07 flat	$3.00 +180.4%	-26.5%	$18.62M	$52.67M	N/A	120	News Coverage
TMDIF Titan Medical	N/A	$0.16 -6.5%	N/A	-58.5%	$18.08M	$17.63M	N/A	50
HIND Vyome	2.8199 of 5 stars	$2.18 -2.7%	$15.00 +588.1%	N/A	$15.72M	$320K	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLGN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. ICU, IRIX, TMDIF, HIND, and ZJYL

How does CollPlant Biotechnologies compare to SeaStar Medical?

Summary

How does CollPlant Biotechnologies compare to IRIDEX?

Summary

How does CollPlant Biotechnologies compare to Titan Medical?

Summary

How does CollPlant Biotechnologies compare to Vyome?

Summary

How does CollPlant Biotechnologies compare to Jin Medical International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. ICU, IRIX, TMDIF, HIND, and ZJYL

How does CollPlant Biotechnologies compare to SeaStar Medical?

Does the media favor CLGN or ICU?

Do analysts prefer CLGN or ICU?

Which has preferable valuation & earnings, CLGN or ICU?

Which has more volatility and risk, CLGN or ICU?

Do insiders and institutionals believe in CLGN or ICU?

Is CLGN or ICU more profitable?

Summary

How does CollPlant Biotechnologies compare to IRIDEX?

Do analysts recommend CLGN or IRIX?

Which has more risk & volatility, CLGN or IRIX?

Which has preferable valuation and earnings, CLGN or IRIX?

Do insiders and institutionals believe in CLGN or IRIX?

Does the media prefer CLGN or IRIX?

Is CLGN or IRIX more profitable?

Summary

How does CollPlant Biotechnologies compare to Titan Medical?

Which has higher earnings & valuation, TMDIF or CLGN?

Do analysts recommend TMDIF or CLGN?

Do insiders & institutionals hold more shares of TMDIF or CLGN?

Does the media refer more to TMDIF or CLGN?

Is TMDIF or CLGN more profitable?

Which has more risk and volatility, TMDIF or CLGN?

Summary

How does CollPlant Biotechnologies compare to Vyome?

Which has higher valuation and earnings, CLGN or HIND?

Does the media favor CLGN or HIND?

Is CLGN or HIND more profitable?

Do analysts rate CLGN or HIND?

Do insiders and institutionals have more ownership in CLGN or HIND?

Which has more risk and volatility, CLGN or HIND?

Summary

How does CollPlant Biotechnologies compare to Jin Medical International?

Do institutionals and insiders have more ownership in CLGN or ZJYL?

Which has stronger valuation and earnings, CLGN or ZJYL?

Does the media favor CLGN or ZJYL?

Which has more volatility and risk, CLGN or ZJYL?

Is CLGN or ZJYL more profitable?

Do analysts prefer CLGN or ZJYL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools